Gilead Sciences (GILD) Operating Expenses (2009 - 2026)

Gilead Sciences has reported Operating Expenses for 18 years, with the latest figure at $4.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 1.26% year-over-year to $4.4 billion; the trailing twelve-month figure through Mar 2026 stood at $19.4 billion (down 5.6% YoY), and the FY2025 full-year result was $19.4 billion, down 28.31% from the prior year.
• Operating Expenses for Q1 2026 stood at $4.4 billion, down from $5.9 billion in the prior quarter.
• The five-year high for Operating Expenses was $11.0 billion in Q1 2024, with the low at $4.2 billion in Q3 2022.
• Historically, Operating Expenses has averaged $5.3 billion across 5 years, with a median of $4.6 billion in 2023.
• Annual changes were most pronounced in 2024 — Operating Expenses soared 136.88% — and 2025, when it tumbled 59.76%.
• Gilead Sciences' Operating Expenses stood at $5.1 billion in 2022, then climbed by 7.42% to $5.5 billion in 2023, then declined by 7.0% to $5.1 billion in 2024, then increased by 16.1% to $5.9 billion in 2025, then slipped by 26.38% to $4.4 billion in 2026.
• The last three Operating Expenses figures came in at $4.4 billion (Q1 2026), $5.9 billion (Q4 2025), and $4.4 billion (Q3 2025), per Business Quant data.